Availability of Cost-effectiveness Studies for Drugs With High Medicare Part D Expenditures

IMPORTANCE: Prescription drug spending in the US requires policy intervention to control costs and improve the value obtained from pharmaceutical spending. One such intervention is to apply cost-effectiveness evidence to decisions regarding drug coverage and pricing, but this intervention depends on...

Descripción completa

Detalles Bibliográficos
Autores principales: Tisdale, Rebecca L., Ma, Iris, Vail, Daniel, Bhattacharya, Jay, Goldhaber-Fiebert, Jeremy D., Heidenreich, Paul A., Sandhu, Alexander T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2021
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8214163/
https://www.ncbi.nlm.nih.gov/pubmed/34143189
http://dx.doi.org/10.1001/jamanetworkopen.2021.13969

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8214163/
https://www.ncbi.nlm.nih.gov/pubmed/34143189
http://dx.doi.org/10.1001/jamanetworkopen.2021.13969

Ejemplares similares